3,4-dihydroxyphenylacetic acid has been researched along with Parkinson Disease in 227 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline." | 7.78 | 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012) |
| "3,4-Dihydroxyphenylacetaldehyde (DOPAL), the monoamine oxidase (MAO) metabolite of dopamine, plays a role in pathogenesis of Parkinson disease, inducing α-synuclein aggregation." | 3.91 | Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy. ( Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM, 2019) |
| "Oxidative deamination of dopamine produces the highly toxic aldehyde 3,4-dihydroxyphenylacetaldehyde (DOPAL), enhanced production of which is found in post-mortem brains of Parkinson disease patients." | 3.81 | Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). ( Araujo, GD; Coelho-Cerqueira, E; Domont, GB; Eliezer, D; Follmer, C; Pinheiro, AS; Yatabe-Franco, DY, 2015) |
| "The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline." | 3.78 | 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012) |
| "The long-term effect of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central monoaminergic neurons in young (2-3 months) and aging (12 months) C57BL/6 mice has been studied using neurochemical and immunocytochemical techniques." | 3.68 | Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. ( Date, I; Felten, DL; Felten, SY, 1990) |
| "In four human controls, four cases of Parkinson's disease and three cases of amyotrophic lateral sclerosis analysis of dopamine, noradrenaline, serotonin and the metabolites 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid was performed in various segments of postmortem spinal cord." | 3.68 | Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. ( Gavranovic, M; Gsell, W; Jellinger, K; Riederer, P; Schmidtke, A; Sofic, E, 1991) |
| "We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease." | 3.68 | GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990) |
| "Mean levels of the two hydrolases angiotensin-converting enzyme (ACE) and acetylcholinesterase (AChE), the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and total protein concentration were examined in cerebrospinal fluid (CSF) samples from a group of patients with dementia of the Alzheimer's type, a group of comparably demented patients with Parkinson's disease, and a neurologically healthy elderly control group." | 3.67 | Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. ( Direnfeld, LK; Langlais, PJ; Marquis, JK; Nixon, RA; Volicer, L; Zubenko, GS, 1986) |
| " Hence, we propose to reevaluate this class of drugs as a disease-modifiers for PD, and we suggest that improved analysis of their pharmacology and bioavailability in the brain, together with a more precise patients stratification, should be considered before planning future clinical trials." | 2.72 | Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. ( Antonini, A; Bubacco, L; Masato, A; Sandre, M, 2021) |
| "The most common is Parkinson's disease (PD), in which putamen dopamine content is drastically reduced." | 2.66 | The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases. ( Goldstein, DS, 2020) |
| "Recent reports indicate that Parkinson's disease (PD) involves specific functional abnormalities in residual neurons - decreased vesicular sequestration of cytoplasmic catecholamines via the vesicular monoamine transporter (VMAT) and decreased aldehyde dehydrogenase (ALDH) activity." | 1.72 | The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease. ( Goldstein, DS; Halperin, R; Landau, R; Leibowitz, A; Sharabi, Y; Sullivan, P; Zibly, Z, 2022) |
| " DOPAL is well known to exhibit toxic effects on neuronal cells." | 1.62 | Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity. ( Ito, S; Ojika, M; Sugumaran, M; Tanaka, H; Wakamatsu, K, 2021) |
| "The synucleinopathies Parkinson's disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF) are characterized by intra-cytoplasmic deposition of the protein alpha-synuclein and by catecholamine depletion." | 1.62 | Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. ( Goldstein, DS; Holmes, C; Lamotte, G; Lenka, A; Sharabi, Y; Sullivan, P, 2021) |
| " Although this effect occurs with the formation of differently toxic products, the molecular basis of this inhibition is still unclear." | 1.62 | Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC. ( Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M, 2021) |
| "In rotenone-pre-treated cells, β-methylphenylalanine significantly increased cell viability and MMP, whereas ROS levels, apoptosis and fragmented mitochondria were reduced." | 1.56 | β-Methylphenylalanine exerts neuroprotective effects in a Parkinson's disease model by protecting against tyrosine hydroxylase depletion. ( Feng, Y; Ma, J; Yuan, L, 2020) |
| "In the catecholaldehyde hypothesis for Parkinson's disease, it is a critical driver of the selective loss of dopaminergic neurons that characterizes the disease." | 1.48 | Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein. ( Bax, A; DuMond, JF; Levine, RL; Monti, S; Werner-Allen, JW, 2018) |
| "We developed a diagnostic method for Parkinson's disease by simultaneously analyzing biogenic amines and their metabolites using reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection (RP-HPLC-IPAD) method." | 1.48 | Development of a diagnostic method for Parkinson's disease by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection. ( Hong, SP; Huh, E; Jeong, JS; Oh, M; Oh, MS, 2018) |
| "In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and α-lipoic acid (C/LA nanomicellar complex) was demonstrated." | 1.48 | Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. ( Berezhnoy, DS; Fedorova, TN; Kulikova, OI; Lopachev, AV; Orlova, VS; Stvolinsky, SL, 2018) |
| "In a model of Parkinson's disease we demonstrate that repeated short-term expression of GDNF restores motor capabilities in 6-OHDA-lesioned rats." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| "Levodopa (l-DOPA, l-3,4-dihydroxyphenylalanine) is the most effective drug in the symptomatic treatment of Parkinson's disease (PD), but chronic use initiates a maladaptive process leading to l-DOPA-induced dyskinesia (LID)." | 1.46 | Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. ( Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H, 2017) |
| "Zonisamide (ZNS) is an effective drug for not only motor symptoms but also non-motor symptoms in Parkinson's disease." | 1.46 | Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. ( Asano, T; Hikawa, R; Takahashi, R; Uemura, MT; Yamakado, H, 2017) |
| " The enhanced stability and bioavailability of PEGylated rhFGF-2 make this molecule a great therapeutic candidate for neurodegenerative diseases such as PD and mood disorders." | 1.42 | PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease. ( Chen, G; Feng, J; Feng, W; Huang, Z; Niu, J; Shi, L; Wang, Y; Ye, C; Zhu, G, 2015) |
| "Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease." | 1.42 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015) |
| "Parkinson disease with orthostatic hypotension (PD + OH) and the parkinsonian form of multiple system atrophy (MSA-P) can be difficult to distinguish clinically." | 1.42 | Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy. ( Goldstein, DS; Holmes, C; Kopin, IJ; Sharabi, Y, 2015) |
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| "The mean Unified Parkinson's Disease Rating Scale scores (UPDRS) and the Parkinson's disease Questionnaire-39 (PDQ-39) were obtained before and after surgery." | 1.42 | Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. ( Asahina, M; Higuchi, Y; Hirano, S; Kuwabara, S; Uchiyama, T; Yamamoto, T; Yamanaka, Y, 2015) |
| "Caffeine is a methylxanthine known as a non-selective inhibitor of A2A and A1 adenosine receptors in the brain and shown to be a neuroprotective drug." | 1.40 | Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. ( Cavalheiro, EA; Cerqueira, GS; Correia, AO; de Barros Viana, GS; de Castro Brito, GA; Machado-Filho, JA; Montenegro, AB; Naffah-Mazzacoratti, Mda G; Neves, KR; Nobre, ME, 2014) |
| "Parkinson's disease is a multifactorial neurodegenerative disorder, characterized by a reduction of dopamine (DA) levels." | 1.40 | Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease. ( Conte, C; Ianni, F; Lisanti, A; Natalini, B; Sardella, R; Scorzoni, S, 2014) |
| "A goldfish (Carassius auratus) model of Parkinson's disease (PD) was constructed by a single dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to previously reported methods." | 1.40 | (1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Kong, L; Li, M; Liu, Q; Lu, Z; Wang, J; Wei, D; Yang, M, 2014) |
| "Following the intraperitoneal administration of silymarin (with MRP1, 2, 4 and 5 inhibitory effects), naringenin (with MRP1, 2 and 4 stimulatory effects), sulfinpyrazone (with MRP1, 4 and 5 inhibitory and MRP2 stimulatory effects) and allopurinol (with MRP4 stimulatory effect in doses of 100 mg/kg, 100 mg/kg, 100 mg/kg and 60 mg/kg, respectively, for one week before and after the administration of MPTP in C57B/6 mice in acute dosing regimen the striatal concentrations of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid has been measured using high-performance liquid chromatography." | 1.39 | Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. ( Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013) |
| " VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
| "ADHs are of interest in Parkinson's disease (PD) since these compounds can be harmful to dopamine (DA) neurons." | 1.38 | Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease. ( Anvret, A; Belin, AC; Duester, G; Felder, MR; Galter, D; Gellhaar, S; Lindqvist, E; Lundströmer, K; Pernold, K; Ran, C; Westerlund, M, 2012) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| "The symptoms of restless legs syndrome (RLS) have a circadian pattern and central nervous system dopamine has been implicated in the pathogenesis of the condition." | 1.35 | Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. ( Engelland, S; Kripke, DF; Parsons, L; Poceta, JS, 2009) |
| "Pure autonomic failure (PAF) and Parkinson's disease (PD) share several clinical laboratory abnormalities; however, PAF is not associated with parkinsonism." | 1.35 | Central dopamine deficiency in pure autonomic failure. ( Bernson, M; Carmona, G; Goldstein, DS; Holmes, C; Imrich, R; Mizrahi, N; Sato, T; Sharabi, Y; Vortmeyer, AO, 2008) |
| "Our data show that disease progression produces an early large decay of DA levels, followed by a stabilization." | 1.35 | Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. ( Brusa, L; Fedele, E; Fornai, F; Galati, S; Hainsworth, AH; Lunardi, G; Moschella, V; Pierantozzi, M; Pisani, A; Rossi, S; Stanzione, P; Stefani, A; Tropepi, D, 2009) |
| "Parkinson's disease is a neurodegenerative disorder associated with progressive loss of dopaminergic cells in the substantia nigra." | 1.33 | Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. ( Cho, Y; Choi, HJ; Hwang, O; Lee, SY, 2005) |
| "The MFB lesion model mimics end-stage Parkinson's disease." | 1.33 | Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. ( Ebinger, G; Michotte, Y; Sarre, S; Yuan, H, 2005) |
| " Because of their ability to combat oxidative stress, diet derived phenolic compounds continue to be considered as potential agents for long-term use in PD." | 1.33 | Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. ( Aruoma, OI; Datla, KP; Dexter, DT; Parkar, S; Rai, DK; Zbarsky, V, 2005) |
| "The aetiology of idiopathic Parkinson's disease (PD) is poorly defined but environmental aggression may be relevant." | 1.33 | Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. ( Cavada, C; Close, RM; Cuadrado, A; de Sagarra, MR; Fernández-Ruiz, J; Jackson-Lewis, V; Montero, C; Rojo, AI; Salazar, M; Sánchez-González, MA, 2006) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a toxic metabolite formed by the oxidative deamination of dopamine." | 1.31 | 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. ( Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A, 2000) |
| "Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone." | 1.31 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002) |
| "L-3,4-Dihydroxyphenylalanine (L-DOPA) is a common and effective treatment for Parkinson's disease, but dyskinesia continues to be a serious adverse effect with chronic use." | 1.31 | Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. ( Akiyama, A; Nakazato, T, 2002) |
| "Investigations of gene therapy for Parkinson's disease have focused primarily on strategies that replace tyrosine hydroxylase." | 1.30 | Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. ( Bencsics, C; Kang, UJ; Wachtel, SR, 1997) |
| "That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons." | 1.30 | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997) |
| " Plasma L-dopa was evaluated in relation to dosage and postdose sampling time in 71 outpatients with Parkinson disease." | 1.29 | Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor. ( Copeland, LG; Dutton, J; Playfer, JR; Roberts, NB, 1993) |
| " Plasma levodopa and levodopa metabolite pharmacokinetic profiles were determined using standard techniques." | 1.29 | A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. ( O'Connell, MT; Patsalos, PN; Quinn, NP; Wenning, GK, 1995) |
| "The oxidant stress theory of Parkinson's disease (PD) hypothesizes that levodopa treatment may be potentially harmful and this is supported by studies demonstrating levodopa toxicity to cultured dopaminergic neurons." | 1.29 | Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. ( Ahlskog, JE; Low, PA; Nickander, KK; O'Brien, JF; Tyce, GM; Uitti, RJ, 1996) |
| "Furthermore, 6 of 15 untreated Parkinson's disease patients (40%) displayed markedly elevated plasma concentrations of the catecholamine MAO metabolites, DOPAC or DOPEG." | 1.29 | Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. ( Ahlskog, JE; Kokmen, E; O'Brien, JF; Petersen, RC; Tyce, GM; Uitti, RJ, 1996) |
| "Six patients with Parkinson's disease (PD) and therapeutic response fluctuations (RF) on levodopa treatment participated in an open-label trial of L-deprenyl (Eldepryl) in conjunction with Sinemet." | 1.28 | L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. ( Cedarbaum, JM; Clark, M; Harts, A; Kutt, H; Silvestri, M, 1990) |
| "In experimental Parkinson's disease, we studied the effects of chronic administration (30 days), withdrawal, and reinstitution of bromocriptine." | 1.27 | Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats. ( Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1986) |
| " These results indicate that chronic administration of either bromocriptine or L-Dopa will reverse the DA receptor denervation supersensitivity in striatum seen following 6-OHDA lesion." | 1.27 | Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. ( Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1984) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| "5 g of levodopa daily for up to six months and in 30 patients receiving levodopa (800-1,000 mg) combined with a dopa decarboxylase inhibitor, benserazide (200-250 mg)." | 1.25 | Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. ( Rinne, UK; Siirtola, T; Sonninen, V, 1975) |
| "We believe that neuropharmacologic bladder neck obstruction may be caused by the alpha-adrenergic properties of the metabolites of levodopa." | 1.25 | Effects of levodopa on the bladder outlet. ( Krane, RJ; Murdock, MI; Olsson, CA; Sax, DS, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (14.10) | 18.7374 |
| 1990's | 46 (20.26) | 18.2507 |
| 2000's | 64 (28.19) | 29.6817 |
| 2010's | 67 (29.52) | 24.3611 |
| 2020's | 18 (7.93) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S | 1 |
| Tanaka, H | 1 |
| Ojika, M | 1 |
| Wakamatsu, K | 1 |
| Sugumaran, M | 1 |
| Landau, R | 1 |
| Halperin, R | 1 |
| Sullivan, P | 10 |
| Zibly, Z | 1 |
| Leibowitz, A | 1 |
| Goldstein, DS | 21 |
| Sharabi, Y | 14 |
| Liguori, C | 1 |
| Stefani, A | 2 |
| Fernandes, M | 1 |
| Cerroni, R | 1 |
| Mercuri, NB | 1 |
| Pierantozzi, M | 2 |
| Fongaro, B | 2 |
| Cappelletto, E | 1 |
| Sosic, A | 1 |
| Spolaore, B | 1 |
| Polverino de Laureto, P | 2 |
| Nadig, APR | 1 |
| Huwaimel, B | 1 |
| Alobaida, A | 1 |
| Khafagy, ES | 1 |
| Alotaibi, HF | 1 |
| Moin, A | 1 |
| Lila, ASA | 1 |
| M, S | 1 |
| Krishna, KL | 1 |
| Zhou, J | 1 |
| Li, J | 1 |
| Papaneri, AB | 1 |
| Cui, G | 1 |
| Jinsmaa, Y | 5 |
| Isonaka, R | 1 |
| Kostrzewa, JP | 1 |
| Kostrzewa, RM | 1 |
| Laranjinha, J | 4 |
| Nunes, C | 4 |
| Ledo, A | 1 |
| Lourenço, C | 1 |
| Rocha, B | 1 |
| Barbosa, RM | 2 |
| Bagnoli, E | 1 |
| Diviney, T | 1 |
| FitzGerald, U | 1 |
| Kao, CY | 1 |
| Xu, M | 1 |
| Wang, L | 1 |
| Lin, SC | 1 |
| Lee, HJ | 1 |
| Duraine, L | 1 |
| Bellen, HJ | 1 |
| Tsai, SY | 1 |
| Tsai, MJ | 1 |
| Feng, Y | 1 |
| Ma, J | 1 |
| Yuan, L | 1 |
| Masato, A | 1 |
| Sandre, M | 1 |
| Antonini, A | 1 |
| Bubacco, L | 1 |
| Holmes, C | 12 |
| Lamotte, G | 1 |
| Lenka, A | 1 |
| Kremer, T | 1 |
| Taylor, KI | 1 |
| Siebourg-Polster, J | 1 |
| Gerken, T | 1 |
| Staempfli, A | 1 |
| Czech, C | 1 |
| Dukart, J | 1 |
| Galasko, D | 1 |
| Foroud, T | 1 |
| Chahine, LM | 1 |
| Coffey, CS | 1 |
| Simuni, T | 1 |
| Weintraub, D | 1 |
| Seibyl, J | 1 |
| Poston, KL | 1 |
| Toga, AW | 1 |
| Tanner, CM | 1 |
| Marek, K | 1 |
| Hutten, SJ | 1 |
| Dziadek, S | 1 |
| Trenkwalder, C | 1 |
| Pagano, G | 1 |
| Mollenhauer, B | 1 |
| Palazzi, L | 1 |
| Leri, M | 1 |
| Acquasaliente, L | 1 |
| Stefani, M | 1 |
| Bucciantini, M | 1 |
| Uemura, MT | 1 |
| Asano, T | 1 |
| Hikawa, R | 1 |
| Yamakado, H | 1 |
| Takahashi, R | 1 |
| Sasidharakurup, H | 1 |
| Melethadathil, N | 1 |
| Nair, B | 1 |
| Diwakar, S | 1 |
| Vanle, BC | 1 |
| Florang, VR | 2 |
| Murry, DJ | 1 |
| Aguirre, AL | 1 |
| Doorn, JA | 3 |
| Hoon, M | 1 |
| Petzer, JP | 1 |
| Viljoen, F | 1 |
| Petzer, A | 1 |
| Werner-Allen, JW | 1 |
| Monti, S | 1 |
| DuMond, JF | 1 |
| Levine, RL | 1 |
| Bax, A | 1 |
| Lopez, GJ | 1 |
| Wu, T | 1 |
| Oh, M | 1 |
| Huh, E | 1 |
| Oh, MS | 1 |
| Jeong, JS | 1 |
| Hong, SP | 1 |
| Kulikova, OI | 1 |
| Berezhnoy, DS | 1 |
| Stvolinsky, SL | 1 |
| Lopachev, AV | 1 |
| Orlova, VS | 1 |
| Fedorova, TN | 1 |
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 3 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Joniec-Maciejak, I | 1 |
| Wawer, A | 1 |
| Turzyńska, D | 1 |
| Sobolewska, A | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Mirowska-Guzel, D | 1 |
| Płaźnik, A | 1 |
| Lima, VA | 1 |
| do Nascimento, LA | 1 |
| Eliezer, D | 2 |
| Follmer, C | 2 |
| Stiles, L | 1 |
| Zheng, Y | 1 |
| Smith, PF | 1 |
| Kumar, VB | 2 |
| Hsu, FF | 2 |
| Lakshmi, VM | 1 |
| Gillespie, KN | 1 |
| Burke, WJ | 6 |
| Pagan, FL | 1 |
| Hebron, ML | 1 |
| Wilmarth, B | 1 |
| Torres-Yaghi, Y | 1 |
| Lawler, A | 1 |
| Mundel, EE | 1 |
| Yusuf, N | 1 |
| Starr, NJ | 1 |
| Arellano, J | 1 |
| Howard, HH | 1 |
| Peyton, M | 1 |
| Matar, S | 1 |
| Liu, X | 2 |
| Fowler, AJ | 1 |
| Schwartz, SL | 1 |
| Ahn, J | 1 |
| Moussa, C | 1 |
| Lv, DJ | 1 |
| Li, LX | 1 |
| Chen, J | 1 |
| Wei, SZ | 1 |
| Wang, F | 1 |
| Hu, H | 1 |
| Xie, AM | 1 |
| Liu, CF | 1 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Huston, JP | 1 |
| Schnitzler, A | 1 |
| Miller, GW | 2 |
| Alter, S | 1 |
| Strong, R | 4 |
| Mash, DC | 3 |
| Kopin, IJ | 10 |
| Han, B | 2 |
| Hu, J | 1 |
| Shen, J | 1 |
| Gao, Y | 1 |
| Lu, Y | 2 |
| Wang, T | 2 |
| Yamamoto, T | 2 |
| Uchiyama, T | 2 |
| Sakakibara, R | 1 |
| Taniguchi, J | 1 |
| Kuwabara, S | 2 |
| Machado-Filho, JA | 1 |
| Correia, AO | 1 |
| Montenegro, AB | 1 |
| Nobre, ME | 1 |
| Cerqueira, GS | 1 |
| Neves, KR | 1 |
| Naffah-Mazzacoratti, Mda G | 1 |
| Cavalheiro, EA | 1 |
| de Castro Brito, GA | 1 |
| de Barros Viana, GS | 1 |
| Plangár, I | 1 |
| Zádori, D | 1 |
| Szalárdy, L | 1 |
| Vécsei, L | 2 |
| Klivényi, P | 1 |
| Feng, G | 1 |
| Zhang, Z | 2 |
| Bao, Q | 1 |
| Zhou, L | 1 |
| Jiang, J | 1 |
| Li, S | 1 |
| Zhu, G | 1 |
| Chen, G | 2 |
| Shi, L | 1 |
| Feng, J | 2 |
| Wang, Y | 2 |
| Ye, C | 1 |
| Feng, W | 1 |
| Niu, J | 1 |
| Huang, Z | 1 |
| Sardella, R | 1 |
| Scorzoni, S | 1 |
| Conte, C | 1 |
| Lisanti, A | 1 |
| Ianni, F | 1 |
| Natalini, B | 1 |
| Casida, JE | 2 |
| Ford, B | 1 |
| Cooney, A | 1 |
| Jin, HJ | 1 |
| Song, MY | 1 |
| Zhao, H | 1 |
| Lu, Z | 1 |
| Wang, J | 2 |
| Li, M | 1 |
| Liu, Q | 1 |
| Wei, D | 2 |
| Yang, M | 1 |
| Kong, L | 1 |
| Nordströma, U | 1 |
| Beauvais, G | 1 |
| Ghosh, A | 1 |
| Pulikkaparambil Sasidharan, BC | 1 |
| Lundblad, M | 1 |
| Fuchs, J | 1 |
| Joshi, RL | 1 |
| Lipton, JW | 1 |
| Roholt, A | 1 |
| Medicetty, S | 1 |
| Feinstein, TN | 1 |
| Steiner, JA | 1 |
| Escobar Galvis, ML | 1 |
| Prochiantz, A | 1 |
| Brundin, P | 1 |
| Saal, KA | 1 |
| Koch, JC | 1 |
| Tatenhorst, L | 1 |
| Szegő, EM | 1 |
| Ribas, VT | 1 |
| Michel, U | 1 |
| Tönges, L | 1 |
| Lingor, P | 1 |
| Konieczny, J | 1 |
| Czarnecka, A | 1 |
| Kamińska, K | 1 |
| Lenda, T | 1 |
| Nowak, P | 2 |
| Sharma, N | 1 |
| Nehru, B | 1 |
| Coelho-Cerqueira, E | 1 |
| Yatabe-Franco, DY | 1 |
| Araujo, GD | 1 |
| Pinheiro, AS | 1 |
| Domont, GB | 1 |
| Higuchi, Y | 1 |
| Asahina, M | 1 |
| Hirano, S | 1 |
| Yamanaka, Y | 1 |
| Rai, SN | 1 |
| Yadav, SK | 1 |
| Singh, D | 1 |
| Singh, SP | 1 |
| Targa, AD | 1 |
| Rodrigues, LS | 1 |
| Noseda, AC | 1 |
| Aurich, MF | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| da Cunha, C | 1 |
| Lima, MM | 1 |
| Andersen, AD | 1 |
| Blaabjerg, M | 1 |
| Binzer, M | 1 |
| Kamal, A | 1 |
| Thagesen, H | 1 |
| Kjaer, TW | 1 |
| Stenager, E | 1 |
| Gramsbergen, JBP | 1 |
| Xu, L | 1 |
| Liu, LX | 1 |
| Chen, WF | 1 |
| Lunardi, G | 1 |
| Galati, S | 1 |
| Tropepi, D | 1 |
| Moschella, V | 1 |
| Brusa, L | 1 |
| Rossi, S | 1 |
| Fornai, F | 1 |
| Fedele, E | 1 |
| Stanzione, P | 1 |
| Hainsworth, AH | 1 |
| Pisani, A | 1 |
| Chung, CY | 1 |
| Koprich, JB | 1 |
| Hallett, PJ | 1 |
| Isacson, O | 1 |
| Whittaker, N | 1 |
| Heredia-Moya, J | 1 |
| Li, XM | 1 |
| Ma, HB | 1 |
| Ma, ZQ | 1 |
| Li, LF | 1 |
| Xu, CL | 1 |
| Qu, R | 1 |
| Ma, SP | 1 |
| Marcellino, D | 1 |
| Suárez-Boomgaard, D | 1 |
| Sánchez-Reina, MD | 1 |
| Aguirre, JA | 1 |
| Yoshitake, T | 1 |
| Yoshitake, S | 1 |
| Hagman, B | 1 |
| Kehr, J | 1 |
| Agnati, LF | 1 |
| Fuxe, K | 1 |
| Rivera, A | 1 |
| di Matteo, V | 1 |
| Pierucci, M | 1 |
| Di Giovanni, G | 1 |
| Dragani, LK | 1 |
| Murzilli, S | 1 |
| Poggi, A | 1 |
| Esposito, E | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Shi, D | 1 |
| Lv, L | 1 |
| Li, L | 2 |
| Gu, P | 1 |
| Gao, J | 1 |
| Miao, Y | 1 |
| Hu, W | 1 |
| Basile, MJ | 1 |
| Belin, AC | 2 |
| Westerlund, M | 2 |
| Anvret, A | 2 |
| Lindqvist, E | 2 |
| Pernold, K | 2 |
| Ogren, SO | 1 |
| Duester, G | 2 |
| Galter, D | 2 |
| Panneton, WM | 1 |
| Gan, Q | 1 |
| Galvin, JE | 2 |
| Gautam, AH | 1 |
| Zeevalk, GD | 3 |
| Anderson, DG | 1 |
| Mariappan, SV | 1 |
| Buettner, GR | 1 |
| Almeida, L | 2 |
| Shchepinov, MS | 1 |
| Chou, VP | 1 |
| Pollock, E | 1 |
| Langston, JW | 2 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Manning-Boğ, AB | 2 |
| Rybakowska, I | 1 |
| Szreder, G | 1 |
| Kaletha, K | 1 |
| Barwina, M | 1 |
| Waldman, W | 1 |
| Sein Anand, J | 1 |
| Ran, C | 1 |
| Gellhaar, S | 1 |
| Lundströmer, K | 1 |
| Felder, MR | 1 |
| Jones, CK | 1 |
| Bubser, M | 1 |
| Thompson, AD | 1 |
| Dickerson, JW | 1 |
| Turle-Lorenzo, N | 1 |
| Amalric, M | 2 |
| Blobaum, AL | 1 |
| Bridges, TM | 1 |
| Morrison, RD | 1 |
| Jadhav, S | 1 |
| Engers, DW | 1 |
| Italiano, K | 1 |
| Bode, J | 1 |
| Daniels, JS | 1 |
| Lindsley, CW | 1 |
| Hopkins, CR | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Meng, T | 1 |
| Zheng, ZH | 1 |
| Liu, TT | 1 |
| Lin, L | 1 |
| Kotraiah, V | 1 |
| Pallares, D | 1 |
| Toema, D | 1 |
| Kong, D | 1 |
| Beausoleil, E | 1 |
| Wey, MC | 1 |
| Fernandez, E | 1 |
| Martinez, PA | 1 |
| Frank, T | 1 |
| Klinker, F | 1 |
| Falkenburger, BH | 1 |
| Laage, R | 1 |
| Lühder, F | 1 |
| Göricke, B | 1 |
| Schneider, A | 1 |
| Neurath, H | 1 |
| Desel, H | 1 |
| Liebetanz, D | 1 |
| Weishaupt, JH | 1 |
| Wu, G | 1 |
| Lu, ZH | 1 |
| Kulkarni, N | 1 |
| Ledeen, RW | 1 |
| Vermeer, LM | 1 |
| Kolasiewicz, W | 1 |
| Kuter, K | 1 |
| Berghauzen, K | 1 |
| Schulze, G | 1 |
| Ossowska, K | 1 |
| Fitzmaurice, AG | 1 |
| Rhodes, SL | 1 |
| Lulla, A | 1 |
| Murphy, NP | 1 |
| Lam, HA | 1 |
| O'Donnell, KC | 1 |
| Barnhill, L | 1 |
| Cockburn, M | 1 |
| Sagasti, A | 1 |
| Stahl, MC | 1 |
| Maidment, NT | 1 |
| Ritz, B | 1 |
| Bronstein, JM | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 1 |
| Thiffault, C | 1 |
| Cory-Slechta, DA | 1 |
| Di Monte, DA | 1 |
| Selikhova, MV | 1 |
| Kogan, BM | 1 |
| Serkin, GV | 1 |
| Gusev, EI | 1 |
| Kato, H | 1 |
| Araki, T | 1 |
| Imai, Y | 1 |
| Takahashi, A | 1 |
| Itoyama, Y | 1 |
| Kaur, D | 1 |
| Yantiri, F | 1 |
| Rajagopalan, S | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| Yang, L | 1 |
| Beal, MF | 1 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
| Andersen, JK | 1 |
| Li, SW | 3 |
| Williams, EA | 1 |
| Nonneman, R | 1 |
| Zahm, DS | 1 |
| Gajjar, TM | 1 |
| Anderson, LI | 1 |
| Dluzen, DE | 3 |
| Romero-Ramos, M | 1 |
| Venero, JL | 1 |
| Garcia-Rodriguez, S | 1 |
| Ayala, A | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Legare, ME | 1 |
| Hanneman, WH | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Youdim, MB | 1 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Datla, KP | 2 |
| Bennett, RD | 1 |
| Zbarsky, V | 2 |
| Ke, B | 1 |
| Liang, YF | 1 |
| Higa, T | 1 |
| Bahorun, T | 1 |
| Aruoma, OI | 2 |
| Dexter, DT | 3 |
| Gluck, MR | 2 |
| Santana, LA | 1 |
| Granson, H | 1 |
| Yahr, MD | 2 |
| Nakao, N | 1 |
| Shintani-Mizushima, A | 1 |
| Kakishita, K | 1 |
| Itakura, T | 1 |
| Wang, X | 2 |
| Zhang, H | 1 |
| Wang, K | 1 |
| He, Q | 1 |
| Agrawal, AK | 1 |
| Shukla, S | 1 |
| Chaturvedi, RK | 1 |
| Seth, K | 1 |
| Srivastava, N | 2 |
| Ahmad, A | 1 |
| Seth, PK | 1 |
| Yuan, H | 2 |
| Sarre, S | 3 |
| Ebinger, G | 3 |
| Michotte, Y | 3 |
| Choi, HJ | 1 |
| Lee, SY | 1 |
| Cho, Y | 1 |
| Hwang, O | 1 |
| Rajda, C | 1 |
| Dibó, G | 1 |
| Bergquist, J | 1 |
| Asanuma, M | 2 |
| Miyazaki, I | 1 |
| Diaz-Corrales, FJ | 1 |
| Shimizu, M | 1 |
| Tanaka, K | 2 |
| Ogawa, N | 2 |
| Sasaki, M | 1 |
| Sanada, H | 1 |
| Parkar, S | 1 |
| Rai, DK | 1 |
| Jiang, H | 2 |
| Jiang, Q | 1 |
| Liu, W | 1 |
| Fitzsimmons, DF | 1 |
| Moloney, TC | 1 |
| Dowd, E | 1 |
| Liu, B | 1 |
| Mazzulli, JR | 1 |
| Mishizen, AJ | 1 |
| Giasson, BI | 1 |
| Lynch, DR | 1 |
| Thomas, SA | 1 |
| Nakashima, A | 1 |
| Nagatsu, T | 1 |
| Ota, A | 1 |
| Ischiropoulos, H | 1 |
| Rojo, AI | 1 |
| Montero, C | 1 |
| Salazar, M | 1 |
| Close, RM | 1 |
| Fernández-Ruiz, J | 1 |
| Sánchez-González, MA | 1 |
| de Sagarra, MR | 1 |
| Jackson-Lewis, V | 3 |
| Cavada, C | 1 |
| Cuadrado, A | 1 |
| Hamaue, N | 1 |
| Ogata, A | 1 |
| Terado, M | 1 |
| Ohno, K | 1 |
| Kikuchi, S | 1 |
| Sasaki, H | 1 |
| Tashiro, K | 1 |
| Hirafuji, M | 1 |
| Minami, M | 1 |
| Landau, AM | 1 |
| Kouassi, E | 1 |
| Siegrist-Johnstone, R | 1 |
| Desbarats, J | 1 |
| Jana, S | 1 |
| Maiti, AK | 1 |
| Bagh, MB | 1 |
| Banerjee, K | 1 |
| Das, A | 1 |
| Roy, A | 1 |
| Chakrabarti, S | 1 |
| Grandoso, L | 1 |
| Ponce, S | 1 |
| Manuel, I | 1 |
| Arrúe, A | 1 |
| Ruiz-Ortega, JA | 1 |
| Ulibarri, I | 1 |
| Orive, G | 1 |
| Hernández, RM | 1 |
| Rodríguez, A | 1 |
| Rodríguez-Puertas, R | 1 |
| Zumárraga, M | 1 |
| Linazasoro, G | 1 |
| Pedraz, JL | 1 |
| Ugedo, L | 1 |
| Poceta, JS | 1 |
| Parsons, L | 1 |
| Engelland, S | 1 |
| Kripke, DF | 1 |
| Recchia, A | 1 |
| Rota, D | 1 |
| Debetto, P | 1 |
| Peroni, D | 1 |
| Guidolin, D | 1 |
| Negro, A | 1 |
| Skaper, SD | 1 |
| Giusti, P | 1 |
| Bentho, O | 1 |
| Sato, T | 2 |
| Moak, J | 1 |
| Imrich, R | 2 |
| Conant, S | 1 |
| Eldadah, BA | 1 |
| Bernson, M | 1 |
| Mizrahi, N | 1 |
| Carmona, G | 1 |
| Vortmeyer, AO | 1 |
| Rajeswari, A | 1 |
| Sabesan, M | 1 |
| Melamed, E | 4 |
| Hefti, F | 2 |
| Liebman, J | 1 |
| Schlosberg, AJ | 1 |
| Wurtman, RJ | 2 |
| Zigmond, MJ | 3 |
| Stricker, EM | 1 |
| Mena, MA | 1 |
| Aguado, EG | 1 |
| de Yebenes, JG | 1 |
| Schneider, MB | 2 |
| Murrin, LC | 2 |
| Pfeiffer, RF | 2 |
| Deupree, JD | 1 |
| Cooper, DR | 1 |
| Marrel, C | 1 |
| Testa, B | 1 |
| van de Waterbeemd, H | 1 |
| Quinn, N | 1 |
| Jenner, P | 2 |
| Marsden, CD | 1 |
| Karoum, F | 1 |
| Chuang, LW | 1 |
| Eisler, T | 1 |
| Calne, DB | 1 |
| Liebowitz, MR | 1 |
| Quitkin, FM | 1 |
| Klein, DF | 1 |
| Wyatt, RJ | 1 |
| Reches, A | 1 |
| Fahn, S | 1 |
| Scatton, B | 1 |
| Rouquier, L | 1 |
| Javoy-Agid, F | 2 |
| Agid, Y | 1 |
| Bierer, DW | 1 |
| Quebbemann, AJ | 1 |
| Hagan, RM | 1 |
| Raxworthy, MJ | 1 |
| Gulliver, PA | 1 |
| Eldrup, E | 1 |
| Mogensen, P | 1 |
| Jacobsen, J | 1 |
| Pakkenberg, H | 1 |
| Christensen, NJ | 1 |
| Tohgi, H | 1 |
| Abe, T | 1 |
| Yamazaki, K | 1 |
| Saheki, M | 1 |
| Takahashi, S | 1 |
| Tsukamoto, Y | 1 |
| Loeffler, DA | 2 |
| LeWitt, PA | 3 |
| DeMaggio, AJ | 2 |
| Juneau, PL | 2 |
| Milbury, PE | 1 |
| Matson, WR | 1 |
| Moukhles, H | 1 |
| Nieoullon, A | 2 |
| Daszuta, A | 1 |
| Finberg, JP | 1 |
| Bankiewicz, KS | 1 |
| Espino, A | 1 |
| Llorens, J | 1 |
| Calopa, M | 1 |
| Bartrons, R | 1 |
| Rodriguez-Farré, E | 1 |
| Ambrosio, S | 1 |
| Wesemann, W | 2 |
| Blaschke, S | 1 |
| Solbach, M | 1 |
| Grote, C | 1 |
| Clement, HW | 1 |
| Riederer, P | 3 |
| Muthane, U | 1 |
| Ramsay, KA | 1 |
| Donaldson, D | 1 |
| Fernando, S | 1 |
| Ferreira, M | 1 |
| Przedborski, S | 2 |
| Hossain, MA | 1 |
| Weiner, N | 1 |
| Sian, J | 1 |
| Rose, S | 1 |
| Hindmarsh, JG | 1 |
| Mann, VM | 1 |
| Cooper, JM | 1 |
| Wells, FR | 1 |
| Daniel, SE | 2 |
| Lees, AJ | 2 |
| Schapira, AH | 1 |
| Mattammal, MB | 2 |
| Chung, HD | 2 |
| Benetello, P | 1 |
| Furlanut, M | 1 |
| Zara, G | 1 |
| Baraldo, M | 1 |
| Hassan, E | 1 |
| Dutton, J | 1 |
| Copeland, LG | 1 |
| Playfer, JR | 1 |
| Roberts, NB | 1 |
| Wenning, GK | 1 |
| O'Connell, MT | 1 |
| Patsalos, PN | 1 |
| Quinn, NP | 1 |
| Haring, JH | 1 |
| Raghu, G | 1 |
| Ahlskog, JE | 2 |
| Uitti, RJ | 2 |
| Low, PA | 1 |
| Tyce, GM | 2 |
| O'Brien, JF | 2 |
| Nickander, KK | 1 |
| Yokoyama, R | 1 |
| Shibata, T | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Hastings, TG | 2 |
| Lewis, DA | 2 |
| Petersen, RC | 1 |
| Kokmen, E | 1 |
| Maruyama, W | 1 |
| Naoi, M | 1 |
| Narabayashi, H | 1 |
| Howells, DW | 1 |
| Liberatore, GT | 1 |
| Wong, JY | 1 |
| Donnan, GA | 1 |
| Tatton, WG | 1 |
| Wadia, JS | 1 |
| Ju, WY | 1 |
| Chalmers-Redman, RM | 1 |
| Tatton, NA | 1 |
| Bowenkamp, KE | 1 |
| Lapchak, PA | 2 |
| Hoffer, BJ | 1 |
| Miller, PJ | 1 |
| Bickford, PC | 1 |
| Havaich, MK | 1 |
| Wachtel, SR | 1 |
| Bencsics, C | 1 |
| Kang, UJ | 1 |
| Boireau, A | 1 |
| Bordier, F | 1 |
| Dubédat, P | 1 |
| Pény, C | 1 |
| Impérato, A | 1 |
| Dluzen, D | 1 |
| Araujo, DM | 1 |
| Hilt, DC | 1 |
| Sheng, J | 1 |
| Jiao, S | 1 |
| Yoshida, K | 1 |
| Higuchi, H | 1 |
| Kamata, M | 1 |
| Yoshimoto, M | 1 |
| Shimizu, T | 1 |
| Hishikawa, Y | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Martínez-Tica, J | 1 |
| Izurieta-Sánchez, P | 1 |
| Spencer, JP | 1 |
| Marsden, DC | 1 |
| Halliwell, B | 1 |
| Zhang, J | 1 |
| Kravtsov, V | 1 |
| Amarnath, V | 1 |
| Picklo, MJ | 1 |
| Graham, DG | 1 |
| Montine, TJ | 1 |
| Moy, LY | 1 |
| Sonsalla, PK | 2 |
| Lamensdorf, I | 1 |
| Eisenhofer, G | 1 |
| Harvey-White, J | 1 |
| Nechustan, A | 1 |
| Kirk, K | 1 |
| Serra, PA | 1 |
| Esposito, G | 1 |
| Enrico, P | 1 |
| Mura, MA | 1 |
| Migheli, R | 1 |
| Delogu, MR | 1 |
| Miele, M | 1 |
| Desole, MS | 1 |
| Grella, G | 1 |
| Miele, E | 1 |
| Rabinovic, AD | 1 |
| Xu, K | 1 |
| Meissner, W | 1 |
| Paul, G | 1 |
| Reum, T | 1 |
| Reese, R | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Kupsch, A | 1 |
| Kristal, BS | 1 |
| Conway, AD | 1 |
| Brown, AM | 1 |
| Jain, JC | 1 |
| Ulluci, PA | 1 |
| Rathke-Hartlieb, S | 1 |
| Kahle, PJ | 1 |
| Neumann, M | 1 |
| Ozmen, L | 1 |
| Haid, S | 1 |
| Okochi, M | 1 |
| Haass, C | 1 |
| Schulz, JB | 1 |
| Tillerson, JL | 1 |
| Cohen, AD | 1 |
| Philhower, J | 1 |
| Schallert, T | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Iacovitti, L | 1 |
| Stull, ND | 1 |
| Jin, H | 1 |
| Lin, TS | 1 |
| Minteer, S | 1 |
| Barthwal, MK | 1 |
| Dikshit, M | 1 |
| Oechsner, M | 1 |
| Buhmann, C | 1 |
| Strauss, J | 1 |
| Stuerenburg, HJ | 1 |
| Nakazato, T | 1 |
| Akiyama, A | 1 |
| Hashimoto, T | 1 |
| Yabe-Nishimura, C | 1 |
| Kirik, D | 1 |
| Rosenblad, C | 1 |
| Burger, C | 1 |
| Lundberg, C | 1 |
| Johansen, TE | 1 |
| Muzyczka, N | 1 |
| Mandel, RJ | 1 |
| Björklund, A | 1 |
| Riaz, SS | 1 |
| Jauniaux, E | 1 |
| Stern, GM | 1 |
| Bradford, HF | 1 |
| Peyrin, L | 1 |
| Cottet-Emard, JM | 1 |
| Claustre, B | 1 |
| Narasimhachari, N | 1 |
| Leiner, K | 1 |
| Brown, C | 1 |
| Hoehn, MM | 3 |
| Crowley, TJ | 2 |
| Rutledge, CO | 3 |
| Bronaugh, RL | 1 |
| MacMurtry, RJ | 1 |
| Murdock, MI | 1 |
| Olsson, CA | 1 |
| Sax, DS | 1 |
| Krane, RJ | 1 |
| Watson, E | 1 |
| Wilk, S | 1 |
| Siirtola, T | 1 |
| Sonninen, V | 1 |
| Rinne, UK | 1 |
| Lach, B | 1 |
| Grimes, D | 1 |
| Benoit, B | 1 |
| Minkiewicz-Janda, A | 1 |
| Russ, H | 1 |
| Mihatsch, W | 1 |
| Gerlach, M | 1 |
| Przuntek, H | 1 |
| Sofic, E | 1 |
| Gsell, W | 1 |
| Gavranovic, M | 1 |
| Schmidtke, A | 1 |
| Jellinger, K | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| Drumheller, A | 1 |
| Prell, GD | 1 |
| Khandelwal, JK | 1 |
| Burns, RS | 1 |
| Blandina, P | 1 |
| Morrishow, AM | 1 |
| Green, JP | 1 |
| Date, I | 1 |
| Felten, DL | 1 |
| Felten, SY | 1 |
| Horellou, P | 1 |
| Marlier, L | 1 |
| Privat, A | 1 |
| Darchen, F | 1 |
| Scherman, D | 1 |
| Henry, JP | 1 |
| Mallet, J | 1 |
| Carlsson, A | 1 |
| Fornstedt, B | 1 |
| Cedarbaum, JM | 1 |
| Silvestri, M | 1 |
| Clark, M | 1 |
| Harts, A | 1 |
| Kutt, H | 1 |
| Harnois, C | 1 |
| Di Paolo, T | 1 |
| Fazzini, E | 1 |
| Durso, R | 1 |
| Davoudi, H | 1 |
| Szabo, GK | 1 |
| Albert, ML | 1 |
| Conte-Devolx, B | 1 |
| Grino, M | 1 |
| Castanas, E | 1 |
| Guillaume, V | 1 |
| Tonon, MC | 1 |
| Vaudry, H | 1 |
| Oliver, C | 1 |
| Parenti, M | 1 |
| Flauto, C | 1 |
| Parati, E | 1 |
| Vescovi, A | 1 |
| Groppetti, A | 1 |
| Shigetomi, S | 1 |
| Stahl, SM | 1 |
| Faull, KF | 1 |
| Barchas, JD | 1 |
| Berger, PA | 1 |
| Collins, MA | 1 |
| Neafsey, EJ | 1 |
| Zubenko, GS | 1 |
| Marquis, JK | 1 |
| Volicer, L | 1 |
| Direnfeld, LK | 1 |
| Langlais, PJ | 1 |
| Nixon, RA | 1 |
| Kenny, AM | 1 |
| Baden, DR | 1 |
| Nakamura, S | 2 |
| Fukuda, H | 1 |
| Hara, K | 2 |
| Fukuyama, H | 1 |
| Kameyama, M | 2 |
| Youngster, SK | 1 |
| Heikkila, RE | 1 |
| Sershen, H | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Iijima, S | 1 |
| Globus, M | 1 |
| Rosenthal, J | 1 |
| Uzzan, A | 1 |
| Yu, PH | 1 |
| Bailey, BA | 1 |
| Durden, DA | 1 |
| Boulton, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?[NCT03104725] | Phase 1 | 6 participants (Actual) | Interventional | 2017-09-25 | Terminated (stopped due to Difficulty with recruitment and participant accrual due to study eligibility criteria and required study procedures (e.g., multiple lumbar punctures).) | ||
| Phase IIb Study of Intranasal Glutathione in Parkinson's Disease[NCT02424708] | Phase 2 | 45 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients with Parkinson's Disease (PD) who took N-acetylcysteine (NAC), and healthy volunteers who did not take NAC, each had two separate lumbar punctures (LPs) to obtain spinal fluid. The spinal fluid samples were used to measure the ratio of the brain chemical called 5-S-cysteinyl-dopamine (Cys-DA) to the brain chemical called 3,4-Dihydroxyphenylacetic acid (Cys-DOPAC). Dopamine has 2 metabolic fates. One is the breakdown of dopamine by an enzyme to form DOPAC. The other is spontaneous oxidation to form Cys-DA. The ratio of Cys-DA/DOPAC may reflect these relative fates. If NAC reduced spontaneous oxidation to Cys-DA, then the ratio Cys-DA/DOPAC would decrease between LP 1 and LP 2, which would be reflected as a percent decrease. (NCT03104725)
Timeframe: All participants underwent a baseline LP. For PD participants, the second LP occurred approximately 2 hours after the participant had taken NAC the last NAC dose. For HV participants the second LP takes place approximately 48 hours after the first LP.
| Intervention | percent change (Mean) |
|---|---|
| Healthy Volunteers (HVs) | 50.1 |
| Parkinson's Disease (PD) Patients | 27.2 |
Patients with Parkinson's Disease (PD) who took N-acetylcysteine (NAC), and healthy volunteers who did not take NAC, each had two separate lumbar punctures (LP 1 and LP 2) to obtain spinal fluid. The spinal fluid samples were used to measure the amount of a brain chemical called 5-S-cysteinyl-dopamine (Cys-DA). The primary outcome measure is the mean change in CSF Cys-DA levels between pre and post-NAC treatment, which is calculated as the difference of CSF Cys-DA levels at pre-treatment (LP 1) and post-treatment (LP 2) divided by CSF Cys-DA at pre-treatment (LP 1). A greater percent decrease in Cys-DA levels in the brain would suggest that NAC may contribute to a reduction in the oxidation of brain dopamine, while a smaller percent decrease would suggest that NAC had no effect on the oxidation of brain dopamine. (NCT03104725)
Timeframe: All participants underwent a baseline LP. For PD participants, the second LP occurred approximately 2 hours after the participant had taken NAC the last NAC dose. For HV participants the second LP takes place approximately 48 hours after the first LP.
| Intervention | percent change (Mean) |
|---|---|
| Healthy Volunteers (HVs) | 45.7 |
| Parkinson's Disease (PD) Patients | 20.1 |
Patients with Parkinson's Disease (PD) who took N-acetylcysteine (NAC), and healthy volunteers who did not take NAC, each had two separate lumbar punctures (LPs) to obtain spinal fluid. The spinal fluid samples were used to measure the ratio of the brain chemical called 5-S-cysteinyl-dopamine (Cys-DA) to the brain chemical called 3,4-Dihydroxyphenylacetic acid (Cys-DOPAC). Dopamine has 2 possible metabolic fates or processes of degradation. One fate is the breakdown of Dopamine by an enzyme to form DOPAC. The other fate is spontaneous oxidation to form Cys-DA. The ratio of Cys-DA to DOPAC may reflect these relative fates. If NAC reduced spontaneous oxidation to Cys-DA, then the ratio Cys-DA/DOPAC ratio would decrease between LP 1 and LP 2. (NCT03104725)
Timeframe: All participants underwent a baseline LP. For PD participants, the second LP occurred approximately 2 hours after the participant had taken NAC the last NAC dose. For HV participants the second LP takes place approximately 48 hours after the first LP.
| Intervention | ratio (Mean) | |
|---|---|---|
| Cys-DA/DOPAC LP1 | Cys-DA/DOPAC LP2 | |
| Healthy Volunteers (HVs) | 0.12 | 0.05 |
| Parkinson's Disease (PD) Patients | 0.16 | 0.13 |
11 reviews available for 3,4-dihydroxyphenylacetic acid and Parkinson Disease
| Article | Year |
|---|---|
The Peculiar Facets of Nitric Oxide as a Cellular Messenger: From Disease-Associated Signaling to the Regulation of Brain Bioenergetics and Neurovascular Coupling.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Brain; Energy Metabolism; Humans; Mitoch | 2021 |
The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Autonomic Nervous System Diseases; Dopamine; Humans; Lewy Body Disea | 2020 |
Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Dopamine; Humans; Oxidative Stress; Parkinson Disease | 2021 |
Nitric oxide and dopamine metabolism converge via mitochondrial dysfunction in the mechanisms of neurodegeneration in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopaminergic Neurons; Humans; Mitochondria; Nitri | 2021 |
The heart of PD: Lewy body diseases as neurocardiologic disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catecholamines; Dopamine; Heart; Humans; Lewy Bodie | 2019 |
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Apoptosis; Catecholamines; Humans; Lipid P | 2014 |
[Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease].
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Humans; Oxidative Stress; Parkinson Disease; Reactive Oxygen | 2011 |
3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Drug Delivery Systems; Humans; Neuroprotective Agents; Park | 2003 |
[3,4-Dihydroxyphenylacetic acid (DOPAC)].
Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Alzheimer Disease; Biomark | 2005 |
Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Dopamine; Humans; Oxidative Stress; Parkinson Disea | 2006 |
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Express | 1996 |
4 trials available for 3,4-dihydroxyphenylacetic acid and Parkinson Disease
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; alpha-Synuclein; Biomarkers; Brain; | 2019 |
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transpla | 2004 |
The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antiparkinson Agents; Biogenic Monoamines; Cerebral Ventricle | 1996 |
Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Aged; Clinical Trials as Topic; Dopamine; Dose | 1975 |
212 other studies available for 3,4-dihydroxyphenylacetic acid and Parkinson Disease
| Article | Year |
|---|---|
Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Neurotoxicity Syndromes; Oxidation-Reduction; Par | 2021 |
The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamines; Dopamine; Parkinson Disease; Rats; Rotenone | 2022 |
Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amyloid beta-Peptides; Biomarkers; Dopamine; Glucose; Humans; Lactat | 2022 |
3,4-Dihydroxyphenylethanol and 3,4-dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α-synuclein at different extent: Insights into the interplay between protein dynamics and catechol effect.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catechols; Dopamine; Humans; Parkinson Disease; Phe | 2022 |
Manganese chloride (MnCl
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; | 2022 |
AJ76 and UH232 as potential agents for diagnosing early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Antagonists; Haloperidol; Homovanillic A | 2023 |
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Do | 2020 |
p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Animals, Newborn; Dopamine; Exocyt | 2020 |
Dysregulation of astrocytic mitochondrial function following exposure to a dopamine metabolite: Implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Dopamine; Mitochondria; Parkinson Disease; Rats | 2021 |
Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Cell Line; Cell Line, Tumor; | 2020 |
β-Methylphenylalanine exerts neuroprotective effects in a Parkinson's disease model by protecting against tyrosine hydroxylase depletion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aminobutyrates; Animals; Cell Survival; Dopamine; Humans; Membrane P | 2020 |
Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Cohort Studies; Dopamine; Dopaminergic Neurons; Female; Homova | 2021 |
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Homovanillic Acid; Humans; Levodopa; Neurotransmitter Agents; Parkin | 2021 |
Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Cell Proliferation; Dopamine; Dopaminergic | 2021 |
Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Astrocytes; Brain; Dopamine; Explorat | 2017 |
A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Biomarkers; Brain; Cell Death; Computer Simulation; | 2017 |
Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Enzyme Induction; Glyceraldehyde-3-Phosphate Dehy | 2017 |
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopami | 2017 |
Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Isoindoles; Models, | 2018 |
Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Biomarkers; Disease Progression; Dopamine; Female; Foll | 2018 |
Development of a diagnostic method for Parkinson's disease by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Biomarkers; Chromatography, High Pressure | 2018 |
Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Carnosine; Dopamine; Homovanillic Acid | 2018 |
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caprylates; C | 2018 |
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylation; alpha-Synuclein; Dopamine; Dopaminergic Neurons; Humans | 2019 |
The effects of electrical stimulation of the peripheral vestibular system on neurochemical release in the rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Electric Stimulation; Electric S | 2018 |
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents; | 2019 |
Sleep deprivation caused a memory defects and emotional changes in a rotenone-based zebrafish model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cognition; Disease Models, Animal; Dopamine; Emotions; Male | 2019 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldeh | 2013 |
Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chalcone; Gene Expression Re | 2013 |
The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Action Potentials; Animals; Biogenic Monoamines; Chromatography, Hig | 2014 |
Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Brain; Caffeine; Cytokines; | 2014 |
Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allopurinol; Animals; | 2013 |
Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Apoptosis; Astrocytes; Behavior, Animal; Biolo | 2015 |
Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebral Cortex; Chromatography, High Pressure Liquid; Chro | 2014 |
Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehydes; Animals; Antifungal Agents; Benom | 2014 |
A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Mo | 2014 |
(1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2014 |
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease | 2015 |
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do | 2015 |
Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biomarkers; Case-Control Studies; Comorbidity; Cross-Sectional | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aldehyde Dehydrogenase; Corpus Striatum; Di | 2015 |
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Cytokines; Disease Models, Animal; Dopaminer | 2016 |
Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Animals; Cell Membrane; Dopamine; Dopamine | 2015 |
Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Area Under Curve; Catecholamines; Deep B | 2015 |
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, | 2016 |
Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2016 |
Unraveling a new circuitry for sleep regulation in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine Agonists; Dopamine D2 Receptor An | 2016 |
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Agents; Monoamine Oxidase; Monoamine Oxi | 2016 |
Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Catechols; Dihydroxyphenylalanine; Dopamine; Female; | 2016 |
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine; | 2017 |
[Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Central Nervous System Agents; Corpus Str | 2008 |
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Aged; Disease Progression; Dopamine; Dyskinesias; Homo | 2009 |
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expressi | 2009 |
Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Chromatography, Liqui | 2010 |
Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Cor | 2010 |
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count; | 2010 |
Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carotenoids; Disease Models, Animal; Dopamine; Functional L | 2009 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson's disease rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antigens, CD; Corpus Striatum; Diseas | 2011 |
Catechols in post-mortem brain of patients with Parkinson disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain Chemistry; Dopamine; Female; Humans; | 2011 |
Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Amphetamine; Analysis of Variance; Animals; A | 2011 |
The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Dopamine; Glial Fibrillary Acidic Protein | 2010 |
Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Electron Transport; Electron Transport Cha | 2011 |
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benzoquinones; Cyclooxygenase 2; Free Radicals; Humans; Oxidation-Re | 2011 |
Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; bcl-2-Associated X Protein; Cell Death; Dop | 2011 |
Natural toxin implicated as triggering Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Humans; Neurons; Neurotoxins; Parkinson Disease | 2011 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Analysis of Variance; Animals; Apomorphine; C | 2012 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression; | 2012 |
Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde De | 2013 |
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Body Weight; Cognition Disorders; C | 2012 |
Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma | 2012 |
Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aging; Animals; Antiparkinson Agents; Blott | 2012 |
Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Catechols; Cell Line; Chromatography, High Pressure Liqui | 2012 |
6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Central Nervous System Stimulants; Cereb | 2012 |
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Benomyl; Dopaminergic Neurons; Flow | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
[Catecholamine metabolism in different forms of Parkinson's disease].
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Data Interpretation, Statistical; Dihydroxyphe | 2002 |
Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Corpus Striatum; Disease Models, An | 2003 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2003 |
Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Drug Interactions; Estrogens; Female; Methampheta | 2003 |
Semichronic inhibition of glutathione reductase promotes oxidative damage to proteins and induces both transcription and translation of tyrosine hydroxylase in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Western; Carmustine; Corpus Striatum; Dopamine; D | 2003 |
Genetic, biochemical, and characterization of neurological mutant 3, a new mouse model for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Chromosome Mapping; Disease Models, Animal | 2003 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Beverages; Corpus Striatum; Dopamine; Dose-Re | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; | 2004 |
Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Differentiation; Cell Division; Cell | 2004 |
Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Transp | 2004 |
Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressur | 2004 |
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine | 2004 |
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Benzoquinones; Biopterins; Cell Death; Cell | 2005 |
Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antiparkinson Agents; Dopamine; Dose-Response Relations | 2005 |
Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Ce | 2005 |
Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC). Implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cell Respiration; Dopamine; Dose-Response Relationsh | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; | 2005 |
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Curcumin; Disease Models, Animal; Dopamine; F | 2005 |
Parkin suppresses the expression of monoamine oxidases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; B-Lymphocytes; Binding Sites; Cell Line, Transformed; Cell | 2006 |
Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatogra | 2006 |
Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Androgens; Animals; Dopamine; Dopamine Agents; Dose-Response Relatio | 2006 |
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell D | 2006 |
Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; | 2006 |
Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; Brain Chemistry; Catecholamines; Dopamine; En | 2006 |
Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Central Nervous System Depressants; Chromatography, High Pr | 2007 |
Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzoquinones; Brain; Dopamine; Electron Transport; Electro | 2007 |
Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Line; Cell Survival; Corpus Striatum | 2007 |
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Monoamines; Chromatography, High Pressure Liquid; Cir | 2009 |
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; A | 2008 |
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Biomarkers; Brain; Dihydroxyphenylalanine; Dop | 2008 |
Central dopamine deficiency in pure autonomic failure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Autonomic Nervous System Diseases; Brain; Catechols; Dihydroxy | 2008 |
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis | 2008 |
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Stem; Disease Models, Animal; Dopa Decarboxylase; Dop | 1980 |
Parkinson's disease: studies with an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dopamine; Electrophysiology; | 1984 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Homovani | 1980 |
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dop | 1984 |
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 1984 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Co | 1982 |
3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug | 1982 |
Dopamine deficiency in the cerebral cortex in Parkinson disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Cerebral Cortex; Dopamine; Hippocampus; Homovanillic Acid; Hum | 1982 |
Interference of levodopa and its metabolites with colorimetry of uric acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Colorimetry; Dopamine; Homovanillic Acid; Humans; Levodopa; Parkinso | 1981 |
Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Benzyl Compounds; Carbidopa; Catechol O-Methyl | 1980 |
CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; | 1995 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Met | 1995 |
Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal | 1995 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanill | 1995 |
Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; gam | 1995 |
Intranigral injected iron progressively reduces striatal dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Ferric Compounds; Injections; Ma | 1994 |
Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biomarkers; Calbindin 1; Calbindins; | 1994 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyc | 1993 |
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Brain Chemistry; Caudate Nucleus; Dopamine; Electron Transport | 1994 |
Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain; Dopamine; Gas Chromatography-Mass Sp | 1993 |
Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Dopamine; Homovanillic Acid; Humans; Levodopa; Neurons; Parki | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed- | 1993 |
Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aromatic Amino Acid Decarboxylase Inhibitor | 1993 |
A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antitubercular Agents; Dopa Decarboxylase; Homovanillic Acid; Humans | 1995 |
An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Culture Techniques; Dopamine; Dopamine Uptake Inhibitors; g | 1995 |
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Cysteinyldopa; Humans; Levodopa; Mal | 1996 |
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz | 1996 |
Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine Agonists; D | 1995 |
Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catechols; Cysteine; Dopamine; Free Radicals; Histocytochem | 1996 |
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Catecho | 1996 |
Dopaminergic responses to striatal damage.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Tissue Transplantation; Corpus Striatum; Dihyd | 1996 |
Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dis | 1997 |
Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Dopamine; Glutathione; Glutathione Di | 1994 |
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cell | 1997 |
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1997 |
Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Estradio | 1997 |
Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; Apomorphine; Behavior, Animal; Disease Models | 1997 |
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Depressive Disorder; Dopamine; Electric Stimulation; Electr | 1998 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Biotransformation; Corpus Striatum; D | 1998 |
Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8,11,14-Eicosatrienoic Acid; Aged; Aged, 80 and over; Chromatography | 1998 |
Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Apoptosis; Catechols; Dopamine; Neurotoxins | 2000 |
Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 3,4-Dihydrox | 2000 |
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Dopamine; Energy | 2000 |
Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Chlorides; Chromatography, H | 2000 |
Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Dopamine; Homovanillic Acid | 2000 |
Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cysteine; Dopamine; Down-Regulation; Extracellular Space; G | 2000 |
The effect of GDNF on nigrostriatal dopaminergic function in response to a two-pulse K(+) stimulation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug | 2000 |
The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Denervation; Dopamine; Electric Stimulation Therapy; Globus | 2000 |
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Aminobenzoic Acid; Aminobenzoates; Animals; Aristolochic Acids; Ce | 2001 |
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line.
Topics: 1-Methyl-3-isobutylxanthine; 3,4-Dihydroxyphenylacetic Acid; Cell Differentiation; Colforsin; Cultur | 2001 |
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Brain; Catechols; Humans; Hydrogen Peroxide; Hydrox | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech | 2002 |
Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Dopam | 2002 |
Oxidative metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde, induces dopamine release from PC12 cells by a Ca2+-independent mechanism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium; Calcium Channel Blockers; Dopamine; L-Lactate Dehy | 2002 |
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Behavior, Animal; Cell Count; Cell Death; | 2002 |
The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain Tissue Transplantation; Brain-Derived Neurotrophic Factor; Cel | 2002 |
Studies on urinary DOPAC in man by means of a sensitive automated procedure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Adult; Aged; Autoanalysis; | 1978 |
The simultaneous determination by selected ion monitoring of the levels of homovanillic, isohomovanillic, 3,4-dihydroxyphenylacetic and 3-methoxy-4-hydroxymandelic acids in single biological samples.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Cats; Chromatography, Gas; Dihydroxyphenyl | 1975 |
The Parkinsonian syndrome and its dopamine correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dopamine; Extrapyramidal Tracts; Female; Homovanillic A | 1977 |
Dopamine correlates of neurological and psychological status in untreated Parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Affect; Aged; Dopamine; Female; Homovanillic Acid; Humans; Le | 1976 |
Effects of levodopa on the bladder outlet.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; M | 1975 |
Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography.
Topics: 3,4-Dihydroxyphenylacetic Acid; Chromatography, Gas; Dopamine; Homovanillic Acid; Levodopa; Parkinso | 1975 |
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; H | 1975 |
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 1992 |
Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Astrocytoma; Biopsy; Catecholamines; Caudate Nucleus; Child; | 1992 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Autopsy; Bio | 1991 |
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Aci | 1991 |
Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Cerebra | 1991 |
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; | 1990 |
Exogeneous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: grafting in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; DNA; Dopamine; Enz | 1990 |
Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catechols; Dopamine; Guinea Pigs; Humans; Oxidation- | 1991 |
L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylami | 1990 |
Decreased dopamine in the retinas of patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Female; Homovanillic Acid; Humans | 1990 |
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1990 |
Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Amines; Corticotropin-Releasing Hormone; Dopamine; Fe | 1985 |
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn | 1986 |
[Clinical significance of 3,4-dihydroxyphenyl acetic acid analysis in endocrine tests of the adrenal medulla and sympathetic nervous system].
Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Adrenal Medulla; Adult; Ag | 1989 |
CSF monamine metabolites in movement disorders and normal aging.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Female; Glycols; Ho | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; Aged; Alzheimer Disease; Cerebrospinal Fluid P | 1986 |
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; D | 1986 |
Biochemical aspects of Parkinson-dementia complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dement | 1988 |
Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 1987 |
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
[Psychiatric symptoms and plasma levodopa dynamics in Parkinson's disease].
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Female; Hallucinations; Humans; L | 1987 |
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Brain; Dopamine; Drug Administration | 1987 |
Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Animals; Blood Platelets; Chromatography, High Pressure L | 1986 |